{"pmid":32437019,"title":"Baricitinib: a chance to treat COVID-19?","text":["Baricitinib: a chance to treat COVID-19?","Currently, there are no approved therapies for the treatment of COVID-19. With most of the world on lockdown and the looming threat of millions of deaths, there is immense pressure to find a therapy for this disease. This article is protected by copyright. All rights reserved.","J Med Virol","Lo Caputo, S","Corso, G","Clerici, M","Santantonio, T A","32437019"],"abstract":["Currently, there are no approved therapies for the treatment of COVID-19. With most of the world on lockdown and the looming threat of millions of deaths, there is immense pressure to find a therapy for this disease. This article is protected by copyright. All rights reserved."],"journal":"J Med Virol","authors":["Lo Caputo, S","Corso, G","Clerici, M","Santantonio, T A"],"date":"2020-05-22T11:00:00Z","year":2020,"_id":"32437019","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1002/jmv.26033","e_drugs":["baricitinib"],"topics":["Case Report"],"weight":1,"_version_":1667521393658429441,"score":9.490897,"similar":[{"pmid":32343423,"title":"A Novel Plan to Deal with SARS-CoV-2 and COVID-19 Disease.","text":["A Novel Plan to Deal with SARS-CoV-2 and COVID-19 Disease.","As we write this report in April 2020, more than two million people worldwide have been infected with the SARS-CoV-2 coronavirus and more than 150,000 have died of COVID-19 disease. International economies have been brought to a standstill, and social isolation based on palpable fear of death remains the order of the day. Appropriately or not, the United States government is talking about resuming work activities and social interaction to boost economic recovery. While this makes financial sense, from a medical perspective our population will be left defenseless in the absence of a viable treatment strategy for SARS-CoV-2. Herein we present a plan to deal with this looming threat. This article is protected by copyright. All rights reserved.","J Med Virol","Stricker, Raphael B","Fesler, Melissa C","32343423"],"abstract":["As we write this report in April 2020, more than two million people worldwide have been infected with the SARS-CoV-2 coronavirus and more than 150,000 have died of COVID-19 disease. International economies have been brought to a standstill, and social isolation based on palpable fear of death remains the order of the day. Appropriately or not, the United States government is talking about resuming work activities and social interaction to boost economic recovery. While this makes financial sense, from a medical perspective our population will be left defenseless in the absence of a viable treatment strategy for SARS-CoV-2. Herein we present a plan to deal with this looming threat. This article is protected by copyright. All rights reserved."],"journal":"J Med Virol","authors":["Stricker, Raphael B","Fesler, Melissa C"],"date":"2020-04-29T11:00:00Z","year":2020,"_id":"32343423","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.1002/jmv.25945","keywords":["covid-19","coronavirus","sars","antibiotics"],"locations":["United States"],"countries":["United States"],"countries_codes":["USA|United States"],"topics":["Prevention","Treatment"],"weight":1,"_version_":1666138495789301760,"score":108.17273},{"pmid":32297987,"title":"Off-label Use of Tocilizumab in Patients with SARS-CoV-2 Infection.","text":["Off-label Use of Tocilizumab in Patients with SARS-CoV-2 Infection.","The spread of the novel-Coronavirus infection worldwide represents a challenge for physicians. Particularly, no approved therapy has demonstrated to have an impact in treating patients who develop severe respiratory insufficiency so far. The use of humanized anti-human inteleukine-6 receptor antibody tocilizumab seems a promising strategy for these patients. This article is protected by copyright. All rights reserved.","J Med Virol","Di Giambenedetto, Simona","Ciccullo, Arturo","Borghetti, Alberto","Gambassi, Giovanni","Landi, Francesco","Visconti, Elena","Zileri Dal Verme, Lorenzo","Bernabei, Roberto","Tamburrini, Enrica","Cauda, Roberto","Gasbarrini, Antonio","32297987"],"abstract":["The spread of the novel-Coronavirus infection worldwide represents a challenge for physicians. Particularly, no approved therapy has demonstrated to have an impact in treating patients who develop severe respiratory insufficiency so far. The use of humanized anti-human inteleukine-6 receptor antibody tocilizumab seems a promising strategy for these patients. This article is protected by copyright. All rights reserved."],"journal":"J Med Virol","authors":["Di Giambenedetto, Simona","Ciccullo, Arturo","Borghetti, Alberto","Gambassi, Giovanni","Landi, Francesco","Visconti, Elena","Zileri Dal Verme, Lorenzo","Bernabei, Roberto","Tamburrini, Enrica","Cauda, Roberto","Gasbarrini, Antonio"],"date":"2020-04-17T11:00:00Z","year":2020,"_id":"32297987","source":"PubMed","week":"202016|Apr 13 - Apr 19","doi":"10.1002/jmv.25897","keywords":["covid-19","sars-cov-2","interstitial pneumonia","tocilizumab"],"e_drugs":["tocilizumab"],"topics":["Case Report"],"weight":1,"_version_":1666138493275865089,"score":88.008354},{"pmid":32410234,"title":"Use of subcutaneous tocilizumab in patients with COVID-19 pneumonia.","text":["Use of subcutaneous tocilizumab in patients with COVID-19 pneumonia.","Over the last months, pandemic SARS-CoV-2 caused a significant challenge for clinicians. Unfortunately, no approved and validated treatments are available. Intravenous tocilizumab, an antirheumatic drug, seems to be promising in counteracting cytokine storm caused by SARS-CoV-2 infection with associated clinical improvements. We report herein a case series of patients with COVID-19 pneumonia who were treated with tocilizumab administrated, for the first time, subcutaneously with good clinical and radiological outcomes. This article is protected by copyright. All rights reserved.","J Med Virol","Mazzitelli, Maria","Arrighi, Eugenio","Serapide, Francesca","Pelle, Maria Chiara","Tassone, Bruno","Lionello, Rosaria","Marrazzo, Giuseppina","Lagana, Domenico","Costanzo, Francesco Saverio","Matera, Giovanni","Trecarichi, Enrico Maria","Torti, Carlo","32410234"],"abstract":["Over the last months, pandemic SARS-CoV-2 caused a significant challenge for clinicians. Unfortunately, no approved and validated treatments are available. Intravenous tocilizumab, an antirheumatic drug, seems to be promising in counteracting cytokine storm caused by SARS-CoV-2 infection with associated clinical improvements. We report herein a case series of patients with COVID-19 pneumonia who were treated with tocilizumab administrated, for the first time, subcutaneously with good clinical and radiological outcomes. This article is protected by copyright. All rights reserved."],"journal":"J Med Virol","authors":["Mazzitelli, Maria","Arrighi, Eugenio","Serapide, Francesca","Pelle, Maria Chiara","Tassone, Bruno","Lionello, Rosaria","Marrazzo, Giuseppina","Lagana, Domenico","Costanzo, Francesco Saverio","Matera, Giovanni","Trecarichi, Enrico Maria","Torti, Carlo"],"date":"2020-05-16T11:00:00Z","year":2020,"_id":"32410234","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1002/jmv.26016","keywords":["covid-19","sars-cov-2","pneumonia","subcutaneous","tocilizumab"],"e_drugs":["tocilizumab"],"topics":["Case Report"],"weight":1,"_version_":1666989866091544577,"score":84.29027},{"pmid":32441773,"title":"COVID-19 in a patient with HIV infection.","text":["COVID-19 in a patient with HIV infection.","The worldwide pandemic of the novel coronavirus disease 2019 (COVID-19) has raised many challenges and uncertainties regarding disease management and prognosis in immunocompromised patient populations. The concurrence of human immunodeficiency virus (HIV) infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of COVID-19, presents an intriguing problem and only a handful of these cases exist in the literature, despite 37.9 million people living with HIV throughout the world. Previous reports suggest the possibility of a protective factor from standard antiretroviral treatment for HIV patients that could have significant clinical benefits for these patients when co-infected with SARS-CoV-2. HIV patients also generally present with atypical clinical presentation and have a less severe form of COVID-19 than the general population. Here, we present the first case of an HIV positive patient who was diagnosed with COVID-19 in the United States. This article is protected by copyright. All rights reserved.","J Med Virol","Patel, Raj H","Pella, Pablo M","32441773"],"abstract":["The worldwide pandemic of the novel coronavirus disease 2019 (COVID-19) has raised many challenges and uncertainties regarding disease management and prognosis in immunocompromised patient populations. The concurrence of human immunodeficiency virus (HIV) infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of COVID-19, presents an intriguing problem and only a handful of these cases exist in the literature, despite 37.9 million people living with HIV throughout the world. Previous reports suggest the possibility of a protective factor from standard antiretroviral treatment for HIV patients that could have significant clinical benefits for these patients when co-infected with SARS-CoV-2. HIV patients also generally present with atypical clinical presentation and have a less severe form of COVID-19 than the general population. Here, we present the first case of an HIV positive patient who was diagnosed with COVID-19 in the United States. This article is protected by copyright. All rights reserved."],"journal":"J Med Virol","authors":["Patel, Raj H","Pella, Pablo M"],"date":"2020-05-23T11:00:00Z","year":2020,"_id":"32441773","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1002/jmv.26049","keywords":["covid-19","hiv","sars-cov-2","antiretroviral","co-infection"],"locations":["United States"],"countries":["United States"],"countries_codes":["USA|United States"],"topics":["Case Report"],"weight":1,"_version_":1667535119509880833,"score":78.2908},{"pmid":32343410,"title":"COVID-19 in Tuberculosis patients: a report of three cases.","text":["COVID-19 in Tuberculosis patients: a report of three cases.","The clinical features and treatment of pulmonary tuberculosis patients with COVID-19 is unclear and understudied. Here, three pulmonary tuberculosis patients with COVID-19 infection were prospectively followed from hospital admission to discharge. We provide information and experience with treatment of pulmonary tuberculosis cases with confirmed COVID-19 infection. This article is protected by copyright. All rights reserved.","J Med Virol","He, Guiqing","Wu, Jing","Shi, Jichan","Dai, Jianyi","Gamber, Michelle","Jiang, Xiangao","Sun, Wenjie","Cai, Jing","32343410"],"abstract":["The clinical features and treatment of pulmonary tuberculosis patients with COVID-19 is unclear and understudied. Here, three pulmonary tuberculosis patients with COVID-19 infection were prospectively followed from hospital admission to discharge. We provide information and experience with treatment of pulmonary tuberculosis cases with confirmed COVID-19 infection. This article is protected by copyright. All rights reserved."],"journal":"J Med Virol","authors":["He, Guiqing","Wu, Jing","Shi, Jichan","Dai, Jianyi","Gamber, Michelle","Jiang, Xiangao","Sun, Wenjie","Cai, Jing"],"date":"2020-04-29T11:00:00Z","year":2020,"_id":"32343410","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.1002/jmv.25943","keywords":["coronavirus","immune responses","infection"],"topics":["Case Report"],"weight":1,"_version_":1666138495812370432,"score":75.60705}]}